ArticleFrontiers in endocrinology2025
Changes of thyroid antibodies after thermal ablation of thyroid nodules: a retrospective study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Thermal ablation (TA) is increasingly used as a minimally invasive treatment for thyroid nodules; however, its influence on thyroid autoimmunity remains unclear. Objective: To investigate longitudinal changes in thyroid autoantibodies and identify relevant risk factors. Methods: This retrospective study included 222 patients who underwent TA between April 2020 and September 2023. Serum levels of anti-thyroglobulin antibody (TGAb), anti-thyroid peroxidase antibody (TPOAb), and thyrotropin receptor antibody (TRAb) were measured at baseline and at 1, 6, 12, and 24 months post-ablation. Antibody trajectories, abnormality rates, and associated risk factors were analyzed. Results: TGAb and TRAb levels increased significantly at all post-ablation time points compared to baseline (all p < 0.05), while TPOAb showed a delayed but significant elevation beginning at 6 months. New-onset antibody positivity was observed in 16.2% of patients, including 9.0% with transient elevations, 4.1% with persistent positivity, and 3.2% with late-onset elevation. Among patients with transient elevations, 93.1% normalized within 24 months. At the 1-month follow-up, patients with benign nodules had more frequent antibody abnormalities than those with papillary thyroid carcinoma (9.5% Conclusion: Thermal ablation was associated with transient increases in thyroid autoantibodies. A baseline TGAb level ≥17.32 IU/mL, elevated TPOAb, and a diagnosis of papillary thyroid carcinoma are associated with increased risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.